NEW YORK, April 11 (GenomeWeb News) - Illumina will genotype prostate cancer samples for Cancer Research UK, the company said today.
Under the agreement, valued at almost $7 million, Illumina will provide genotyping services to researchers at Cancer Research UK, a non-profit research organization. Initially, Ilumina will conduct whole-genome genotyping for at least 4,000 prostate patients samples and controls. In a second phase, the company will develop a custom, 12-sample BeadChip that it will use to genotype at least 8,000 samples. Illumina will use its Sentrix BeadChips and Infinium assay for the project.
The goal is to identify potential cancer biomarkers, and to analyze chromosomal aberrations.
This is the second genotyping service agreement between the two partners in the last six months. In November, Cancer Research UK selected Illumina to provide genotyping services for colorectal cancer.